PHI with Hereditary telangiectasia

How does this condition affect your private health insurance?

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu disease, is an autosomal dominant genetic disorder characterized by abnormal blood vessel formation. This leads to telangiectasias, which are small dilated blood vessels appearing as red spots on the skin and mucous membranes, often causing recurrent nosebleeds (epistaxis) and gastrointestinal bleeding. More critically, HHT can cause arteriovenous malformations (AVMs) in vital organs like the lungs, brain, and liver. These AVMs bypass capillaries, leading to potential hemorrhages, strokes, heart failure, and pulmonary complications. Early diagnosis and management are crucial to prevent life-threatening complications. The severity varies widely among affected individuals.

PKV Risk Assessment

High Probability of Rejection

However, some specialized PHI providers may insure you with a surcharge of up to 40%.

This is a preliminary assessment. For a detailed and binding risk assessment, .

Impact on Your Insurance Policy

Duration of Illness (Initial)

Acute bleeding episodes (hours to days), but the underlying vascular abnormalities are chronic and may present with various symptoms over time.

Duration of Illness (Lifetime)

Lifelong, chronic disease with varying symptom severity and potential for progressive complications.

Cost of Treatment (Initial)

Variable; from moderate for simple epistaxis management to high for acute AVM rupture or severe gastrointestinal bleeding requiring hospitalization and intervention.

Cost of Treatment (Lifetime)

High to very high, involving regular specialist consultations, diagnostic imaging (MRI, CT, echocardiogram), endoscopy, blood transfusions, and potentially repeated embolizations or surgeries for AVMs and bleeding management.

Mortality Rate

Significant, primarily due to complications from arteriovenous malformations (AVMs) in vital organs (e.g., brain hemorrhage, pulmonary hemorrhage, high-output heart failure) if left undiagnosed or untreated. With proper management, mortality has decreased but remains a risk.

Risk of Secondary Damages

High. Includes chronic iron deficiency anemia, neurological deficits (from brain AVMs or strokes), pulmonary hypertension, heart failure, liver cirrhosis, and psychological impact of chronic illness and bleeding.

Probability of Full Recovery

Virtually none, as it is a genetic, chronic condition. Symptoms and complications can be managed effectively, but the underlying vascular abnormalities persist.

Underlying Disease Risk

Low for other distinct primary genetic diseases; however, manifestations of HHT (e.g., anemia, stroke) may initially be investigated as separate conditions before an HHT diagnosis is made.

The information provided is for general informational purposes only and is not a substitute for professional medical or insurance advice. Always consult with a qualified professional for any health concerns or before making any insurance decisions.